11:37:05 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
Kancera är ett läkemedelsbolag. Bolaget utvecklar läkemedel som motverkar skador vid akut och kronisk inflammation. Produkterna utvecklas i första hand för att motverka hyperinflammation vid olika sjukdomstillstånd och därmed skydda vitala organ, till exempel i samband med hjärtinfarkt och svåra virusinfektioner. Kancera planerar två kliniska fas II-studier, i covid-19 och i hjärtpatienter. Kancera bedriver forskning och utveckling inom Karolinska Institutet Science Park i Stockholm.

Kalender

2023-02-21 Bokslutskommuniké 2022
2022-11-18 Kvartalsrapport 2022-Q3
2022-08-19 Kvartalsrapport 2022-Q2
2022-05-27 Ordinarie utdelning KAN 0.00 SEK
2022-05-25 Årsstämma 2022
2022-05-20 Kvartalsrapport 2022-Q1
2022-02-18 Bokslutskommuniké 2021
2021-11-19 Kvartalsrapport 2021-Q3
2021-08-20 Kvartalsrapport 2021-Q2
2021-05-27 Ordinarie utdelning KAN 0.00 SEK
2021-05-26 Årsstämma 2021
2021-05-21 Kvartalsrapport 2021-Q1
2021-02-24 Split KAN 10:1
2021-02-19 Bokslutskommuniké 2020
2020-11-20 Kvartalsrapport 2020-Q3
2020-08-21 Kvartalsrapport 2020-Q2
2020-05-29 Ordinarie utdelning KAN 0.00 SEK
2020-05-28 Årsstämma 2020
2020-05-22 Kvartalsrapport 2020-Q1
2020-04-09 Extra Bolagsstämma 2020
2020-02-21 Bokslutskommuniké 2019
2020-01-31 Extra Bolagsstämma 2019
2020-01-13 Extra Bolagsstämma 2019
2019-11-22 Kvartalsrapport 2019-Q3
2019-05-28 Ordinarie utdelning KAN 0.00 SEK
2019-05-27 Årsstämma 2019
2019-05-24 Kvartalsrapport 2019-Q1
2019-05-23 Kvartalsrapport 2019-Q2
2019-02-22 Bokslutskommuniké 2018
2018-11-23 Kvartalsrapport 2018-Q3
2018-08-24 Kvartalsrapport 2018-Q2
2018-05-31 Ordinarie utdelning KAN 0.00 SEK
2018-05-30 Årsstämma 2018
2018-05-28 Kvartalsrapport 2018-Q1
2018-04-20 Extra Bolagsstämma 2018
2018-02-20 Bokslutskommuniké 2017
2017-11-17 Kvartalsrapport 2017-Q3
2017-09-28 Extra Bolagsstämma 2017
2017-08-22 Kvartalsrapport 2017-Q2
2017-05-31 Ordinarie utdelning KAN 0.00 SEK
2017-05-30 Årsstämma 2017
2017-05-19 Kvartalsrapport 2017-Q1
2017-02-21 Bokslutskommuniké 2016
2016-11-18 Kvartalsrapport 2016-Q3
2016-08-19 Kvartalsrapport 2016-Q2
2016-05-29 Ordinarie utdelning KAN 0.00 SEK
2016-05-26 Årsstämma 2016
2016-05-03 Kvartalsrapport 2016-Q1
2016-04-22 Extra Bolagsstämma 2016
2016-02-19 Bokslutskommuniké 2015
2015-11-20 Kvartalsrapport 2015-Q3
2015-08-21 Kvartalsrapport 2015-Q2
2015-05-29 Ordinarie utdelning KAN 0.00 SEK
2015-05-28 Årsstämma 2015
2015-05-22 Kvartalsrapport 2015-Q1
2015-02-20 Bokslutskommuniké 2014
2014-11-21 Kvartalsrapport 2014-Q3
2014-08-22 Kvartalsrapport 2014-Q2
2014-05-27 Ordinarie utdelning KAN 0.00 SEK
2014-05-26 Årsstämma 2014
2014-05-23 Kvartalsrapport 2014-Q1
2014-02-22 Bokslutskommuniké 2013
2013-11-08 Kvartalsrapport 2013-Q3
2013-10-30 Extra Bolagsstämma 2013
2013-08-23 Kvartalsrapport 2013-Q2
2013-05-29 Ordinarie utdelning KAN 0.00 SEK
2013-05-28 Årsstämma 2013
2013-05-24 Kvartalsrapport 2013-Q1
2013-02-22 Bokslutskommuniké 2012
2012-11-22 Kvartalsrapport 2012-Q3
2012-08-23 Kvartalsrapport 2012-Q2
2012-05-29 Ordinarie utdelning KAN 0.00 SEK
2012-05-28 Årsstämma 2012
2012-05-24 Kvartalsrapport 2012-Q1
2012-02-23 Bokslutskommuniké 2011
2011-11-24 Kvartalsrapport 2011-Q3
2011-11-10 Extra Bolagsstämma 2011
2011-08-31 Kvartalsrapport 2011-Q2
2011-05-30 Ordinarie utdelning KAN 0.00 SEK
2011-05-27 Årsstämma 2011
2011-05-24 Kvartalsrapport 2011-Q1
2022-09-22 08:46:00

Kancera AB (publ) is today reporting new results that confirm that the company’s Fractalkine-blocking candidate drug may increase the efficacy of platinum-based chemotherapy and reduce tumor growth in animal models of ovarian cancer. As a result, Kancera has met the criteria that were set for the scientific evaluation of the project and decided to proceed in applying for regulatory approval to conduct clinical studies of KAND567 in ovarian cancer patients relapsing from platinum-based chemotherapy.

Approximately 300,000 women annually are diagnosed with ovarian cancer in US and Europe. The disease is often diagnosed at a late stage – stage III or later – and as a consequence the probability of five years survival is less than 30%. The current standard of care is surgery followed by platinum-based chemotherapy. This treatment is however limited in efficacy as cancer cells develop resistance to chemotherapy through the ability to repair the DNA damage that chemotherapy causes.

The new preclinical results strengthen the hypothesis that our Fractalkine-blocking drugs are acting through two mechanisms that each have the potential to increase the efficacy of standard-of-care chemotherapy given to patients with ovarian cancer in late progress stage. These results in combination with the encouraging feedback on the clinical relevance that we have received from leading physicians in the field, create a solid foundation for advancing this project further into clinical studies”, says Thomas Olin, CEO of Kancera.

Kancera has previously published results from its preclinical research in the leading scientific magazine Cancers. These results showed that Kancera’s Fractalkine-blocking drugs inhibit cancer cells’ DNA repair after platinum-based chemotherapy, leading to a restored sensitivity to chemotherapy treatment.

Kancera has now confirmed in mouse studies that treatment with its Fractalkine-blocking drugs in combination with platinum-based chemotherapy reduces tumor volume, even in a cancer cell line that is platinum resistant and highly aggressive. The effect can be associated with DNA damage and cancer cell death. In addition, the new studies show that the treatment causes reduced numbers of cells in the microenvironment of the cancer cell that protects the tumor from platinum-based chemotherapy.

Kancera has made the decision to conduct a fully financed phase Ib-study of KAND567 in ovarian cancer patients that have relapsed after platinum-based chemotherapy. The goal is to file a regulatory application during the fourth quarter this year and initiate the study in the first half of 2023. The study will be conducted in collaboration with leading academic hospitals and investigators in the Nordics. Subject to a positive study outcome, Kancera is planning to continue its drug development within cancer using its second-generation drug candidate KAND145. The advantage of starting the clinical development in ovarian cancer with KAND567 and then switch over to KAND145 is that clinical studies can be initiated earlier. In parallel with the clinical studies of KAND567 in ovarian cancer, the company is advancing its development of KAND145, aiming to initiate phase Ia studies during the first half of 2023. In this way, KAND145 will be available for continued clinical studies if the studies with KAND567 confirm the treatment concept. KAND145 has certain product characteristics which make it more suitable for treatment of solid tumors compared to KAND567.

About Kancera AB (publ)
Kancera AB is developing a new class of drugs in the areas of inflammation and cancer, with a main focus on developing drug candidates based on the so-called Fractalkine system. Fractalkine is a natural master regulator that controls with precision immune cells and cancer cells. Kancera is studying its most advanced drug candidate in an ongoing fully financed phase IIa study in inflammation in connection with myocardial infarction. Patient enrollment is expected to be completed before end of 2022. Kancera is also conducting development of its drug candidate KAND145, primarily aimed for oncology indications. Fully financed phase I-studies are planned to start in H1 2023. The stock is traded on the Nasdaq First North Premier Growth Market.

For further information:
Thomas Olin
Chief Executive Officer, Kancera AB
Tel: +46-8-5012 6080

Welcome to visit Kancera’s web page: https://www.kancera.com/en